Menarini's Non-Invasive Prenatal Testing Technology Surpasses Standard Screening

Menarini's Non-Invasive Prenatal Testing Technology Surpasses Standard Screening

Luisa Rossi
2 min read

Groundbreaking Results Unveiled by Menarini in Prenatal Testing Technology

Menarini has revealed the groundbreaking outcomes of a study proving the superiority of their non-invasive prenatal testing technology over standard non-invasive prenatal cell-free DNA (cfDNA) screening in identifying fetal abnormalities. The company's test isolates fetal cells from maternal blood to screen for genomic abnormalities, including trisomic conditions and genome-wide microdeletions and microduplications as small as 600Kb. According to Menarini, this method demonstrated high concordance with invasive diagnostic procedures.

The study, presented at the 21st World Congress of the Fetal Medicine Foundation in Portugal, involved over 1,000 women. Professor Jon Hyett, Head of Maternal and Fetal Medicine at Liverpool Hospital, emphasized the potential of this technology to provide clinically relevant and actionable information about fetal genomic abnormalities with higher resolution and accuracy than existing tests.

Key Takeaways

  • Menarini's non-invasive prenatal test detects fetal genomic abnormalities with high accuracy.
  • The test isolates fetal cells from maternal blood for genomic analysis.
  • The study included over 1,000 women, detecting microdeletions and microduplications down to 600Kb.
  • The test identifies trisomies beyond those detected by standard non-invasive cfDNA analysis.
  • Early detection of fetal genomic abnormalities provides actionable insights for clinical management.


The advanced prenatal testing by Menarini could potentially disrupt the market, offering enhanced detection accuracy to benefit expectant mothers and healthcare providers. This innovation might urge competitors like Nexen Biotech and BillionToOne to expedite their own advancements. In the long term, Menarini's technology could standardize prenatal care, reducing invasive procedures and associated risks. This news could also lead to a positive reaction in the financial markets, boosting Menarini's stock and attracting investments into the prenatal tech sector.

Did You Know?

  • Non-invasive Prenatal Testing (NIPT):
    • Explanation: A method used to analyze fetal DNA present in the mother's blood to detect genetic abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome, among others. Unlike invasive procedures like amniocentesis, NIPT does not carry the risk of miscarriage and can be performed earlier in pregnancy.
  • Cell-free DNA (cfDNA) Screening:
    • Explanation: Involves the analysis of small DNA fragments circulating in the mother's bloodstream, which originate from both the mother and the fetus. This technology is used to screen for chromosomal abnormalities in the fetus, offering a safer alternative to traditional invasive prenatal diagnostic tests.
  • Microdeletions and Microduplications:
    • Explanation: Refers to small deletions or duplications of genetic material within chromosomes, which can lead to various genetic disorders and are often not detected by standard karyotyping. Advanced genomic technologies, like those used in Menarini's test, can detect these small-scale abnormalities, providing more detailed information about fetal health.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings